8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 16, 2009

IMMUNOSYN CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware	005-82677	20-5322896
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4225 Executive Square, Suite 260,

La Jolla, CA 92037

(Address of Principal Executive Offices and Zip Code)

(888) 853-3663

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14A-12)

   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SECTION 5 – Corporate Governance and Management

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)   After the close of business on March 16, 2009, representatives of Immunosyn Corporation (the “Corporation”) received the resignation of Myron W. Wentz, Ph.D., Chairman of the Board of USANA Health Sciences, Incorporated, as a member of the Board of Directors of the Corporation requesting to be effective as of March 13, 2009.

As part of the Stock Purchase and Option Agreement dated March 13, 2008 between Dr. Wentz and Argyll Biotechnologies LLC, the Corporation’s largest shareholder (“Argyll Biotech”), pursuant to which Dr. Wentz purchased 400,000 shares of the Corporation’s Common Stock, as previously disclosed, Argyll Biotech agreed to nominate and/or cause Dr. Wentz (or his designee) to be elected to the Corporation’s Board of Directors at each annual meeting of stockholders for so long as Dr Wentz owns at least 200,000 shares of the Corporation’s Common Stock and Argyll Biotech agreed to vote all, or cause (to the extent within its control) to be voted all, shares of the Corporation’s Common Stock owned or controlled by Argyll Biotech, directly or indirectly, to be voted to elect Dr. Wentz or his designee to serve on the Corporation’s Board of Directors for so long as Dr. Wentz owns at least 200,000 shares of the Corporation’s Common Stock.  Dr. Wentz has reserved any rights he may have under this agreement or any other agreement with the Corporation or Argyll Biotech notwithstanding his resignation.

The Corporation will seek a candidate to fill this vacancy on its Board of Directors in the near future.

Section 9 – Financial Statements and Exhibits

Item 9.01.  Financial Statements and Exhibits.

(d)  Exhibits.

The following exhibit is filed with this Current Report.

Exhibit Number	Description
99.1	Press Release dated March 20, 2009 regarding the resignation of Dr. Myron Wentz from the Company’s Board of Directors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf of the undersigned, hereunto duly authorized.

Dated:  March 20, 2009	IMMUNOSYN CORPORATION
	By:	/s/ Douglas A. McClain, Jr.
		Douglas A. McClain, Jr.
		Chief Financial and Accounting Officer

EX-99.1

Exhibit 99.1

The Blaine Group, Inc.

A Total Communications Agency

8665 Wilshire Blvd., Suite #301, Beverly Hills, CA 90211

310/360-1499 · 310/360-1498 FAX · E-mail:  blaine@pacificnet.net

FOR IMMEDIATE RELEASE: March 20, 2009                                           

FOR FURTHER INFORMATION, CONTACT:  Bill Kraus/Lisa Baker/Devon Blaine The Blaine Group 310/360-1499 310/360-1498 (FAX) blaine@blainegroupinc.com

DR. MYRON WENTZ RESIGNS FROM IMMUNOSYN BOARD OF DIRECTORS

March 20, 2009

La Jolla, CA … PR Newswire… Immunosyn Corporation (IMYN.OTC.BB) has announced that Dr. Myron Wentz has resigned from the Board of Directors of Immunosyn Corporation for personal reasons.

Dr. Wentz is increasing his focus on his humanitarian and charitable endeavors, recently founding the Wentz Medical Centre and Laboratory in Uganda and the Wentz Medical Centre in Cambodia to serve children in those countries orphaned by diseases such as malaria and HIV.

Dr. Myron Wentz states that, “I continue my interest in Immunosyn’s efforts through Argyll Biotechnologies, LLC to seek approvals and commercialization of SF-1019. I plan to use the resources available to me to assist in any appropriate way so that SF-1019 can eventually be used at Sanoviv Medical Institute.”

Dr. Wentz founded Sanoviv with a vision to heal the world of debilitating disease. In June 2007, Dr. Wentz was a recipient of the Albert Einstein Award for Outstanding Achievement in the Life Sciences. In 2006, Dr. Wentz was a recipient of the Children's Champion Award by Children's Hunger Fund, for which he travels worldwide as a medical missionary.

“We appreciated Dr. Wentz’s expertise during his time on the Board of Directors of Immunosyn and look forward to working with him in the future,” commented Stephen D. Ferrone, CEO and President of Immunosyn Corporation.

About Immunosyn Corporation

La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs).  Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe.  Research suggests that SF-1019 has the potential to affect a number of clinical conditions including auto-immune disorders such as Multiple Sclerosis (MS), neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS) and complications from Diabetic Mellitus such Diabetic Neuropathy (DN) and Diabetic Ulcers (DU).